JPRN-jRCT2080221562未知3 期
ong-term study of TAK-875
TAKEDA PHARMACEUTICAL COMPANY LTD.0 个研究点开始时间: 2011年9月5日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •1. The subject is an outpatient.
- •2. The subject signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
排除标准
- •1. The subject has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease.
- •2. The subject is considered ineligible for the study for any other reason by the investigator or subinvestigator.
研究者
相似试验
未知
3 期
Open-label study of TAK-875Diabetes mellitusJPRN-jRCT2080221565TAKEDA PHARMACEUTICAL COMPANY LTD.
未知
3 期
Double-blind comparative study of TAK-875Diabetes mellitusJPRN-jRCT2080221564TAKEDA PHARMACEUTICAL COMPANY LTD.
未知
3 期
Double-blind comparative study of TAK-875Diabetes mellitusJPRN-jRCT2080221774TAKEDA PHARMACEUTICAL COMPANY LTD.
已完成
3 期
Long-term Study of TAK-875Diabetes MellitusNCT01433406Takeda1,222
进行中（未招募）
1 期
ong-term Safety and Tolerability of TAK-881 in Subjects with Primary Immunodeficiency Diseases (PIDD)Primary Immunodeficiency DiseasesMedDRA version: 20.0Level: PTClassification code: 10064859Term: Primary immunodeficiency syndrome Class: 100000004850CTIS2023-505946-24-00Takeda Development Center Americas Inc.39